NCT00650572 - A Study of ARRY-380 in Patients With Advanced HER2+ Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Cancer

Interventions

DRUG

ARRY-380, HER2 inhibitor; oral

Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.

Trial Locations (4)

The University of Texas, MD Anderson Cancer Center, Houston

The University of Colorado Cancer Center, Aurora

British Columbia Cancer Agency, Vancouver

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston